Pharming Group N.V [PHAR] vs Harmony Biosciences [HRMY] Detailed Stock Comparison
Pharming Group N.V
NASDAQ
Loading...
Harmony Biosciences
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Pharming Group N.V wins in 4 metrics, Harmony Biosciences wins in 14 metrics, with 0 ties. Harmony Biosciences appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Pharming Group N.V | Harmony Biosciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 69.31 | 10.97 | Harmony Biosciences |
| Price-to-Book Ratio | 38.60 | 2.53 | Harmony Biosciences |
| Debt-to-Equity Ratio | 53.57 | 22.43 | Harmony Biosciences |
| PEG Ratio | N/A | 0.04 | N/A |
| EV/EBITDA | 386.44 | 6.79 | Harmony Biosciences |
| Profit Margin (TTM) | -2.41% | 23.42% | Harmony Biosciences |
| Operating Margin (TTM) | 3.27% | 24.03% | Harmony Biosciences |
| EBITDA Margin (TTM) | 3.27% | 24.03% | Harmony Biosciences |
| Return on Equity | -3.70% | 27.58% | Harmony Biosciences |
| Return on Assets (TTM) | 2.85% | 14.10% | Harmony Biosciences |
| Free Cash Flow (TTM) | $-2.59M | $218.67M | Harmony Biosciences |
| 1-Year Return | 95.73% | -16.76% | Pharming Group N.V |
| Price-to-Sales Ratio (TTM) | 2.72 | 2.53 | Harmony Biosciences |
| Enterprise Value | $10.19B | $1.67B | Pharming Group N.V |
| EV/Revenue Ratio | 29.99 | 2.16 | Harmony Biosciences |
| Gross Profit Margin (TTM) | 90.38% | 80.97% | Pharming Group N.V |
| Revenue per Share (TTM) | $5 | $14 | Harmony Biosciences |
| Earnings per Share (Diluted) | $-0.14 | $3.10 | Harmony Biosciences |
| Beta (Stock Volatility) | 0.59 | 0.84 | Pharming Group N.V |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Pharming Group N.V vs Harmony Biosciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Pharming Group N.V | -0.81% | -3.80% | 29.91% | 26.99% | 89.66% | 40.34% |
| Harmony Biosciences | -3.08% | -10.00% | -8.68% | -2.82% | -3.60% | -7.01% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Pharming Group N.V | 95.73% | 31.54% | -5.84% | -5.84% | -5.84% | -5.84% |
| Harmony Biosciences | -16.76% | -26.12% | -3.60% | -10.03% | -10.03% | -10.03% |
News Based Sentiment: Pharming Group N.V vs Harmony Biosciences
Pharming Group N.V
News based Sentiment: POSITIVE
Pharming Group delivered strong Q2 results, raised guidance, and continues to attract institutional investment. While recent trading has shown some volatility, the overall narrative is positive, driven by revenue growth and a positive analyst outlook. The appointment of a new CFO adds another layer to the story.
Harmony Biosciences
News based Sentiment: POSITIVE
While the Q2 earnings slightly missed expectations, Harmony Biosciences demonstrated continued revenue growth and outlined a clear strategic vision for future product launches and market expansion. The strong institutional support and positive analyst ratings suggest confidence in the company's long-term prospects, making September a positive month overall.
Performance & Financial Health Analysis: Pharming Group N.V vs Harmony Biosciences
| Metric | PHAR | HRMY |
|---|---|---|
| Market Information | ||
| Market Cap | $953.47M | $1.91B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 9,864 | 769,677 |
| 90 Day Avg. Volume | 12,955 | 615,932 |
| Last Close | $14.68 | $32.39 |
| 52 Week Range | $7.10 - $17.08 | $26.47 - $41.61 |
| % from 52W High | -14.05% | -22.16% |
| All-Time High | $21.99 (Dec 21, 2020) | $62.08 (Dec 05, 2022) |
| % from All-Time High | -33.24% | -47.83% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.26% | 0.16% |
| Quarterly Earnings Growth | 0.26% | 2.43% |
| Financial Health | ||
| Profit Margin (TTM) | -0.02% | 0.23% |
| Operating Margin (TTM) | 0.03% | 0.24% |
| Return on Equity (TTM) | -0.04% | 0.28% |
| Debt to Equity (MRQ) | 53.57 | 22.43 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.35 | $13.44 |
| Cash per Share (MRQ) | $0.18 | $9.83 |
| Operating Cash Flow (TTM) | $31.05M | $259.38M |
| Levered Free Cash Flow (TTM) | $23.18M | $197.81M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Pharming Group N.V vs Harmony Biosciences
| Metric | PHAR | HRMY |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 69.31 | 10.97 |
| Forward P/E | 293.70 | 10.43 |
| PEG Ratio | N/A | 0.04 |
| Price to Sales (TTM) | 2.72 | 2.53 |
| Price to Book (MRQ) | 38.60 | 2.53 |
| Market Capitalization | ||
| Market Capitalization | $953.47M | $1.91B |
| Enterprise Value | $10.19B | $1.67B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 29.99 | 2.16 |
| Enterprise to EBITDA | 386.44 | 6.79 |
| Risk & Other Metrics | ||
| Beta | 0.59 | 0.84 |
| Book Value per Share (MRQ) | $0.35 | $13.44 |
Financial Statements Comparison: Pharming Group N.V vs Harmony Biosciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PHAR | HRMY |
|---|---|---|
| Revenue/Sales | $93.22M | $184.73M |
| Cost of Goods Sold | $8.97M | $31.99M |
| Gross Profit | $84.25M | $152.74M |
| Research & Development | $23.70M | $34.54M |
| Operating Income (EBIT) | $9.00M | $56.25M |
| EBITDA | $9.79M | $66.98M |
| Pre-Tax Income | $7.08M | $57.18M |
| Income Tax | $2.53M | $11.62M |
| Net Income (Profit) | $4.55M | $45.56M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PHAR | HRMY |
|---|---|---|
| Cash & Equivalents | $60.09M | $489.00M |
| Total Current Assets | $214.11M | $642.69M |
| Total Current Liabilities | $77.54M | $175.12M |
| Long-Term Debt | $110.36M | $158.18M |
| Total Shareholders Equity | $215.29M | $720.53M |
| Retained Earnings | $-292.80M | $47.78M |
| Property, Plant & Equipment | $24.23M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PHAR | HRMY |
|---|---|---|
| Operating Cash Flow | $2.07M | $36.44M |
| Capital Expenditures | N/A | $-128,000 |
| Free Cash Flow | $-56,000 | $33.86M |
| Debt Repayment | $-715,000 | $-3.75M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PHAR | HRMY |
|---|---|---|
| Shares Short | 1,414 | 4.27M |
| Short Ratio | 0.14 | 7.11 |
| Short % of Float | 0.00% | 0.16% |
| Average Daily Volume (10 Day) | 9,864 | 769,677 |
| Average Daily Volume (90 Day) | 12,955 | 615,932 |
| Shares Outstanding | 680.31M | 57.14M |
| Float Shares | 670.71M | 50.65M |
| % Held by Insiders | 0.00% | 0.11% |
| % Held by Institutions | 0.00% | 0.95% |
Dividend Analysis & Yield Comparison: Pharming Group N.V vs Harmony Biosciences
| Metric | PHAR | HRMY |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |